Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion
Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of cancer. The drug will be used in combination with Keytruda (pembrolizumab), Merck’s blockbuster drug with a recorded USD 3.8 Billion sales in 2017.
Lundbeck planning to buy Prexton therapeutics for its phase 2 Parkinson’s drug
In a recent deal Lundbeck is paying USD 123 Million up front to buy Prexton Therapeutics and its phase 2 Parkinson’s diseas...
